News coverage about McKesson (NYSE:MCK) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. McKesson earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.9326147679145 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Global Vendor Neutral Archive Market – Merge Healthcare Incorporated, McKesson Corporation, GE Healthcare Limited (theanalystfinancial.com)
- McKesson Corporation: How Biopharmaceutical Manufacturers Can Commercialize New Gene Therapies (twst.com)
- Global Wireless Electronic Records Market – eClinicalWorks, McKesson Corporation, NextGen Healthcare (journalhealthcare.com)
- Southside Quarter preparing for new McKesson building (jaxdailyrecord.com)
- McKesson Is Undervalued (seekingalpha.com)
NYSE MCK traded up $5.03 on Monday, reaching $147.88. 3,442,430 shares of the stock traded hands, compared to its average volume of 1,777,712. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.61 and a current ratio of 1.07. The firm has a market cap of $29,475.57, a P/E ratio of 12.74, a PEG ratio of 1.31 and a beta of 1.32. McKesson has a 12 month low of $133.82 and a 12 month high of $178.86.
The company also recently declared a quarterly dividend, which was paid on Monday, April 2nd. Shareholders of record on Thursday, March 1st were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Wednesday, February 28th. McKesson’s payout ratio is currently 11.71%.
A number of research analysts recently commented on the company. Robert W. Baird reissued a “buy” rating and issued a $200.00 price target on shares of McKesson in a report on Wednesday, January 17th. Zacks Investment Research upgraded McKesson from a “hold” rating to a “buy” rating and set a $164.00 price objective on the stock in a research note on Wednesday, February 14th. Evercore ISI initiated coverage on McKesson in a research note on Thursday, January 4th. They set an “outperform” rating and a $179.00 price objective on the stock. ValuEngine cut McKesson from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Barclays initiated coverage on McKesson in a research note on Thursday, March 8th. They set an “equal weight” rating and a $165.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $176.32.
In other news, SVP Erin M. Lampert sold 1,413 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $149.38, for a total transaction of $211,073.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “McKesson (MCK) Receives Daily News Impact Score of 0.14” was originally published by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://weekherald.com/2018/04/16/mckesson-mck-earns-daily-news-sentiment-rating-of-0-14.html.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.